Immunotherapy of AML: future directions

• Published in: Journal of clinical pathology Vol. 53; no. 1; pp. 49 - 54
• Main Authors: Lowdell, Mark W, Koh, Mickey B C
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and Association of Clinical Pathologists 01-01-2000; BMJ; BMJ Publishing Group LTD
• Subjects: Acute Disease; Antineoplastic agents; Biological and medical sciences; Bone marrow; Bone Marrow Transplantation - adverse effects; Chemotherapy; Cytotoxicity; Graft vs Host Disease - immunology; Graft vs Host Disease - prevention & control; Humans; Immunity, Cellular; Immunotherapy; Immunotherapy - methods; Leukemia, Myeloid - immunology; Leukemia, Myeloid - surgery; Leukemia, Myeloid - therapy; Lymphocytes; Medical sciences; Millennial Review; Pharmacology. Drug treatments; Radiation therapy; Stem cells; Success; Transplants & implants; Human; Treatment; Acute; Immunotherapy; Malignant hemopathy; Autologous system; Review; Allogeneic system; Acute myelocytic leukemia
• ISSN: 0021-9746; 1472-4146
• DOI: 10.1136/jcp.53.1.49

Immunotherapy in the form of allogeneic GvL has been curing AML patients for nearly 30 years but our understanding of the mechanisms has been poor. Our rapidly evolving understanding of the human immune system and the concomitant technical developments in ex vivo cell manipulation, the vision of funding bodies, the dedication of clinical and research staff, and above all the commitment of our patients, promise substantial progress in the treatment of this disease in the year 2000 and beyond.